Dyslipidemia Market 2020-2026 Growth Prospects, Key Vendors and Future Scenario | Major Gaints – Catabasis Pharmaceuticals, Cerenis, Cipla Inc., CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo
In Dyslipidemia Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and charts which eases the understanding of facts and figures. A proficient data and excellent forecasting techniques used in this report are synonymous with accurateness and correctness. Dyslipidemia Market report is a painstaking analysis of existing scenario of the market which covers several market dynamics. The market study of this global Dyslipidemia Market business report takes into consideration market attractiveness analysis where each segment is benchmarked based on its market size, growth rate & general attractiveness.
Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dyslipidemia-market
Global dyslipidemia market is expected to rise gradually to an estimated value of USD 27.52 billion by 2026, registering a CAGR of 10.50% in the forecast period of 2019-2026 with the annual sales of USD 12.38 billion in the year of 2018. This rise in market value can be attributed to the increase in prevalence and awareness along with concerns regarding the health of patients.
Few of the major competitors currently working in the Dyslipidemia market are AstraZeneca (UK), Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla Inc., CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, Lupin Pharmaceuticals and few among others.
Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc/?dbmr=global-dyslipidemia-market
Market Definition: Global Dyslipidemia Market
Dyslipidemia is a condition in which the levels of lipids (cholesterol, triglycerides, or both) or low high-density lipoprotein (HDL) cholesterol level elevated due to multiple reasons including lifestyle, genetics-disorders, drugs etc.
According to World Health Organization, there were approximately 17.9 million people in 2016, who died from cardiovascular diseases, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.
Segmentation: Global Dyslipidemia Market
Dyslipidemia Market : Dyslipidemia Market : By Product type
- Statin Drugs
- Non-Statin Lipid–Lowering Drugs
- Primary dyslipidemia
- Secondary dyslipidemia
Dyslipidemia Market : By Distribution Channel
- Hospitals Pharmacies
- Drug Store
- Online Pharmacies
- Retail Pharmacies
Dyslipidemia Market : By End- User
- Hospital and Clinics
- Medical laboratories
Dyslipidemia Market : By Geography
- North America
- South America
- Middle East & Africa
Dyslipidemia Market Drivers
- Increase in global geriatric population
- Increase in prevalence of lifestyle diseases
- Rise in acceptance of telemental health
- Increase in availability of generic drugs
Dyslipidemia Market Restraints
- Lack of R&D initiatives in this area.
- patent expiry for some blockbuster drugs
- Fewer Government initiatives taken in this direction.
Key Developments in the Dyslipidemia Market:
- In the year 2018, Sanofi and Regeneron Pharmaceuticals, Inc. announced that Praluent (alirocumab) in phase 3 clinical trialdemonstrated the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event such as a heart attack.
- In the year 2018, Amgen Inc. announced the launch of Repatha (Evolocumab) in the US for the indication of heart attacks and stroke due to high cholesterol at a reduced price to gain more customers.
- In the year 2015, WuXi PharmaTech announced its partnership with Eli Lilly to develop, manufacture, and commercializes in China a Lilly-discovered oral experimental drug for cardiovascular risk in patients with dyslipidemia.
Want Full Report? Enquire Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-dyslipidemia-market
About Data Bridge Market Research:
Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
- CDN Newswire